One Platform.
Endless Possibilities.

May 2021

NASDAQ: RCEL ASX: AVH

Legal Disclaimers

Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVD-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning us and such risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and our most recent Annual Report on Form 10-K for the year ended June 30, 2020. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

The Company has filed a registration statement (including a prospectus) and will also file a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) for the offering to which this communication relates, and such registration statement has been declared effective by the SEC. Before you invest, you should read the preliminary prospectus supplement (when available) and the prospectus contained in the registration statement for more complete information about the Company and this offering. The preliminary prospectus supplement (when available) and the registration statement (including the prospectus) may be accessed through the SEC's website at www.sec.gov

AVITA Medical’s products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events.

In the United States, RECELL is approved for use in patients 18 years and older suffering acute thermal burns. Use of RECELL® in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only).

Experienced Leadership Team

Dr. Michael S. Perry
CEO
>30 years experience

Affiliations:
- NOVARTIS
- Schering-Plough
- BAY CITY CAPITAL
- Baxter
- GENETIC THERAPY, INC.

Michael Holder
CFO
30 years experience

Affiliations:
- ImmuneCyte
- PREMIER
- CAROLINA LONGEVITY INSTITUTE

Erin Liberto
CCO
19 years experience

Affiliations:
- Johnson & Johnson
- Allergan

Andrew Quick
CTO
25 years experience

Affiliations:
- Boston Scientific
- AB
- sonova
- SonaMed Corp

Kathy McGee
COO
25 years experience

Affiliations:
- Shire
- at advanced tissue
- Smith+Nephew

Dona Shiroma
General Counsel
20 years experience

Affiliations:
- ASCEND THERAPEUTICS A BESINS HEALTHCARE Company Innovators in Women's Health
- PDL BioPharma
- Johnson & Johnson

AVITA Medical: Investment Highlights

RECELL® System: FDA approved for the treatment of acute thermal burns

- Proprietary Spray-On Skin™ Cells offers life changing benefits
  Point of care technology that is safe & effective
- Published health economic model demonstrates hospital cost savings

Deep scientific and clinical pedigree

- 2 randomized controlled trials and 1st PMA in burns in > 20yrs
- 10,000+ patients, 180+ publications and presentations

Ongoing platform expansion: $1.5B U.S. serviceable market opportunity

- Platform technology with numerous adjacent applications
- PMA label expansion underway with 3 pivotal studies:
  - Vitiligo
  - Soft Tissue Reconstruction
  - Pediatrics (Scalds – early intervention)

Further potential for cell-based gene therapy and aesthetics

Fiscal Q3 RECELL System sales of $4.7M; total revenue of $8.8M (incl. BARDA)

Cash as of 31 March 2021 $115M



Zed, treated with the RECELL System

Revolutionary treatment using a patient's own skin for life-changing outcomes

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only.. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved.

One Platform. Endless Possibilities.

RECELL®
Autologous Cell Harvesting Device

RECELL delivers healthy skin cells



Free cells modulate and catalyze the healing process

RECELL enables regeneration of healthy skin



Technology platform benefits a wide array of skin defects and wounds irrespective of etiology

- Vitiligo
- Trauma
- Burns / Scalds
- Chronic Wounds
- Scar Revision
- Infectious Disease
- Cancer Reconstruction
- Genodermatoses
- Regenerative Dermatology

In the U.S., RECELL is approved for acute thermal burns in patients >18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

First Indication: Thermal Burns
Current Standard of Care Is Suboptimal and Expensive

SPLIT-THICKNESS SKIN GRAFTS (STSG) ARE THE STANDARD OF CARE (SoC)



Harvesting skin from donor site for STSG



Donor site wound created while harvesting skin for autograft



Typical SoC donor site scar 52 weeks post procedure

KEY SHORTCOMINGS OF SoC

- Extensive skin harvesting required
- Pain associated with donor site
- Extended hospitalization and costs
- Multiple complex, costly, surgical procedures
- Risk of infection
- Pigmentation and discoloration
- Scarring
- Atrophy
- Contracture



Current SoC for a 40% Total Body Surface Area (TBSA) burn:
Average cost USD $579,000 and 59.4 days in hospital[1]

1. Kowal, S et al. Cost-effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States. Advances in Therapy.
For more information on RECELL's indication for use.

RECELL Spray-On Skin
Treats 80cm^2 of Skin from a 1cm^2 Biopsy

avita medical

AUTOLOGOUS
Cell Harvesting Device that delivers Spray-On Skin Cells within 30 minutes at the point of care

ACTIVATED
Fresh (non-cultured cells) with the "free edge healing cascade"

DONOR SPARING
Treatment area = 80x donor area (credit card size skin sample can treat an entire adult back)



COMPLETE
Full range of skin cell types with re-pigmentation

SAFE & EFFECTIVE
2 randomized controlled trials supporting PMA
1st PMA burn product approval ~20 yrs
10K+ patients worldwide
>150 peer reviewed articles

PUBLISHED HEALTH ECONOMIC DATA
Demonstrating significant savings to the health care system

1st Premarket Approval Treatment in Burns in 20 Years

Dual multi-center, randomized, controlled premarket approval studies

Pivotal Trial #1 (101 Patients)
RECELL (alone) versus SoC (STSG) in Second-Degree Burns

Published in JBCR and Presented at ABA



Decrease in donor site pain and scarring

- Significantly less donor site pain (p≤0.0025)
- Significantly better donor site appearance (p≤0.0025)
- Significantly reduced donor site scarring (p≤0.0025)
- Significantly greater incidence of donor-site healing at two weeks (p<0.001)

Pivotal Trial #2 (31 Patients)
RECELL (with widely expanded graft) versus STSG in Third-Degree Burns

Published in Burns and Presented at ABA



Robust outcomes despite less donor skin

- RECELL System achieved definitive closure comparable to Standard of Care with significantly less donor skin
- At eight weeks post treatment, 92% of the burn sites treated with the RECELL System achieved complete healing versus 85% for the sites treated with the standard of care

Comparable healing and long-term outcomes for burn sites with significantly less donor skin required

RECELL "Free Edge" Advantage

Healing Process without RECELL

Free edge limits signaling
to wound boundary
(i.e. outside → in)



Healing Process with RECELL

Spray-On Skin Cells signal
from within the wound
(i.e. inside → out)





RECELL Delivers Life-Changing Outcomes

Case series presented at 50th Annual ABA Meeting (2018)

Treatment Day | Day 7 | Day 21 | 3 Months | 1 Year



- Compassionate Use case
- 12-year-old girl with 2nd-degree facial burn and widespread 3rd-degree burns
- 62% Total Body Surface Area (TBSA) burn injury
- Insufficient donor skin available for SoC (STSG)

- Reintroduction of melanocytes resulted in an excellent cosmetic outcome
- No facial contracture release surgery required
- Discharged in 24 days

1 Year



Skin + **Color** Restoration

RECELL's treatment area is **80 times larger** than the donor site

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. This case study was a compassionate use case in which RECELL was used as an investigational device.

Published Health Economic Model: Demonstrates Patient and Health Care System Benefits

RECELL saves the hospital money in in-patient scenarios where the burn is 10% Total Body Surface Area (TBSA) or greater

Transforming Care

Can reduce costs and accelerate recovery by decreasing the number of painful procedures and length of stay in hospital



Fewer procedures and faster healing times get patients home more quickly



Reduced donor site size and greater meshing ratio enables permanent closure with fewer invasive autograft procedures

Shorter and fewer procedures, decreased length of stay, and reduced resource use translates into burn center savings

VALIDATED MODEL

- 21 abstracts on RECELL health economics since launch
- 17+ Burn Centers contributing to the RECELL abstracts and publications
- Two publications
- Customized Budget Impact calculator
- Leader of health economics in burns

1. Park JH, Heggie KM, Edgar DW, Bulsara MK, Wood FM. Does the type of skin replacement surgery influence the rate of infection in acute burn injured patients? Burns 2013;39:1386-90. https://doi.org/10.1016/j.burns.2013.03.015
2. Kowal, S., Kruger, E., Bilir, P. et al. Adv Ther (2019). https://doi.org/10.1007/s12325-019-00961-2

Strong Adoption of the RECELL System



Accomplishments Since Approval

- 81% Burn Surgeons Certified
- 73% Burn Sites Activated
- >3,300 Procedures

Over $35 Million in U.S. RECELL Revenue Since Approval

Data is compiled based on information provided by our customers and is subject to change.

Intellectual Property: Robust and Expanding Patent Estate

ROBUST PROTECTION ACROSS PATENT FAMILIES

Cell Suspension Preparation Technique and Use	Commercial RECELL device, composition of matter, and associated methods of use
Cell Suspension And Use Thereof	Method of preparing cell suspension with exogenous agent to promote wound healing
Systems and Methods for Tissue Processing and Preparation of Cell Suspension Therefrom	Automated system for preparing cell suspension, next generation sprayer and method of production
Devices, Methods, and Kits for Preparing a Cell Suspension	All-in-one RECELL kit, system, and associated method of use
Methods for Identifying Cell Suspensions with Therapeutic Potential for Skin Regeneration	Method and system for validating the use of a cell suspension for administration to a patient
Bioactive Therapeutic Suspensions with Cellular-Based Supernatant	Bioactive suspension derived from freshly disaggregated tissue, and associated methods of preparation and use

EXPANDING PORTFOLIO TO SUPPORT CURRENT AND FUTURE INDICATIONS



Next Generation RECELL devices to improve ease of use in burns and pipeline indications

Potential to license patented technology for telomerase mRNA that has the potential to reverse aging of skin cells

Potential to license technologies for suspension-based delivery of genetically modified cells, with applications to genetic skin disorders

A global total of 56 granted patents, 19 pending patent applications.
Expiration from 2022 to 2040

Note: AVITA owns granted patents in Austria, Australia, Belgium, Brazil, France, Germany, Hong Kong, Italy, Japan, Netherlands, Portugal, Spain, Sweden, Turkey, United Kingdom and USA. AVITA Medical owns pending patent applications in Brazil, Canada, China, EPO (Europe), Hong Kong and USA. Patent count as of 5/14/2021

Development Pipeline and Growth Potential

Focused Pipeline with Strong Growth Potential



* Pediatric Scalds is a BARDA-funded study under contract HHS0100201500028C. Epidermolysis Bullosa and Rejuvenation programs are in partnership with the Gates Center at the University of Colorado and Houston Methodist Research Institute

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Current Platform Enables Access to a Large Serviceable Market



	Thermal Burns	Vitiligo	Trauma	Pediatric Scalds	Total Potential Opportunity
RECELL Eligible Patients at Target Call Point	~25,000	~185,000	~65,000	~13,000	

Efficacy Well Demonstrated

	Patients (in studies)	Publications & Presentations
BURNS	1,656	172
DEFECTS/ VITILIGO	435	56
ACUTE WOUNDS	71	24

Highly De-risked Pipeline with > 10,000 Patients Treated Globally

A common goal: Full skin restoration (Re-epithelialization and re-pigmentation)

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Vitiligo: Unmet Need, No FDA-Approved Products

SIGNIFICANT UNMENT NEED

No FDA-approved medical treatments;
extremely low patient and physician satisfaction with existing products

Vitiligo impacts quality of life (QoL) –
25% of patients with vitiligo reported a DLQI >10, which indicates severe QoL reductions, compared with 34% in psoriasis patients

LIMITED TREATMENT OPTIONS

DRUGS AND PHOTOTHERAPY

Medical management

For disease stabilization: Cortico-steroids, calcineurin inhibitors

2 treatments per week for 3-6 months

- Limited efficacy
  Poor compliance
- Potential skin atrophy, cancer risk

Phototherapy

For disease stabilization: UVB, excimer laser

2-3 treatments / week for a few months to over a year

- Typically combined with topicals
- Not durable

Combination PUVA

(psoralen with phototherapy)

SURGICAL

Skin grafting

For repigmentation of stable lesions (rarely performed): Punch & suction blister grafting

Transplantation of small sections of pigmented skin to depigmented areas

Melanocyte-keratinocyte transplantation

For repigmentation of stable lesions: Requires substantial laboratory equipment

Note: Surgical approaches are performed very rarely and only at very specialized academic centers

Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017.
Willingness-to-Pay and Quality of Life in Patients with Vitiligo. Radtke, et al. BJD. 2009.

In the United States, RECELL is not approved for use with patients suffering vitiligo.

Established RECELL Track Record in Vitiligo

1,000 patients treated internationally and 8 peer-reviewed publications showing positive outcomes

AT 6 MONTHS
RECELL-treated area was 100% re-pigmented



POTENTIAL RECELL BENEFITS

For stable vitiligo of all types (segmental & non-segmental)

Durable: One-time treatment to regenerate pigmentation

Complementary to existing products and pipeline (e.g., immunomodulating drugs and phototherapy that stabilize the disease)

> *Very exciting and novel. Preliminary efficacy rate looks very impressive.*
>
> **– Vitiligo Specialist**

U.S. Pivotal Study enrolling; last patient (N=84) expected in H2 2021

In the United States, RECELL is not approved for use with patients suffering vitiligo.

Traumatic Soft Tissue Injury: High Confidence in Positive Outcomes

RECELL used by multiple surgeons in traumatic wounds with **positive outcomes**

TREATMENT DAY



Patient treated for necrotizing fasciitis.

1 YEAR
POST-RECELL TREATMENT



Excellent healing, with very good cosmetic and functional outcomes.

RECELL demonstrated a compelling value proposition in these **particular wound** types:

- Abrasions
- Degloving Injuries
- Infectious Disease (e.g., Necrotizing Fasciitis)

Soft tissue injuries are associated with large areas of skin loss. As such, the unmet needs are closely aligned with burns.

U.S. Pivotal Study (N=65) enrolling now

Images courtesy of Dr. K. Foster, Arizona Burn Center. In the U.S., RECELL is approved for acute thermal burns in patients > 18 years. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Early Intervention for Pediatric 2nd Degree Burns (Scalds)

A unique subset of burns

- 30% of burns occur between 1 and 15 years of age of which 45% are estimated to be associated with scalds
- Scalds frequently present as "indeterminate depth", for which conventional treatment involves waiting several weeks and only autografting if necessary
- With RECELL early intervention, the aim is to prevent autografting and avoid scarring and disfigurement

BEFORE TREATMENT



3 WEEKS
POST-RECELL TREATMENT



10 WEEKS
POST-RECELL TREATMENT



10 MONTHS
POST-RECELL TREATMENT



Case Study: 2-year-old with scald treated with RECELL

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved.

Exploring Cell-Based Gene Therapy for Epidermolysis Bullosa

THE CHALLENGE



DEBILITATING
Skin fragility, disability, cancer

HIGH UNMET NEED
No FDA-approved treatment, only palliative measures

COST BURDEN
Care of $200K-$500K per year per patient

THE OPPORTUNITY

Preclinical research partnership underway, exploring the combination of a novel gene correction approach with AVITA's Spray-On Skin™ Cells technology

	AVITA AND GATES CENTER COLLABORATION	COMPETITOR PIPELINE PROGRAMS
	Gates Center for Regenerative Medicine, University of Colorado / Anschutz Medical Campus	
CURATIVE	Technology for precise correction of genetic defect & banking for future use	Majority focused on ameliorating symptoms, or based on foreign DNA insertion, which could have negative long-term effects
EFFICIENT	Suspension-based approach eliminates growth & transport of skin sheets	Some competitors focused on growth of gene-edited skin sheets, which suffer from fragility
CONVENIENT	Suspension-based product simplifies application onto patient wounds	Epidermal sheets require surgical anchoring and can result in complex procedures and issues with 'take rates'

Proof-of-concept for delivering genetically modified cells in suspension expected in 2021

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Exploring Novel RNA-Based Approach for Rejuvenation



HOUSTON Methodist LEADING MEDICINE

- **Patented RNA technology** for delivery of telomerase enzyme to aged cells
- **Demonstrated reversal of aging** and return of functionality in cells of progeria patients (human model of accelerated aging)

avita medical

- Patented and proprietary **Spray-On Skin Cells technology and device (RECELL)**
- **Expertise in skin** regeneration, including in preclinical models
- Strong track record and expertise in clinical development and commercialization

Multi-Billion Dollar Market Presents a Sizeable Opportunity

- **>$16.5B** spent in aesthetic procedures per year (US)*
- **>3M** aesthetic procedures per year (US) aimed to improve skin tightness, texture & evenness in skin tone*
- Consumers **desire superior results** over current offerings
- **Personalized, cellular-level approaches** to skin rejuvenation, developed with robust evidence, is an area of significant interest

Sponsored research underway exploring use of telomerase for molecular reversal of skin cell aging

*American Society for Plastic Surgery Annual reports – 2018 and 2019. 2. Goddard et al. Aesthetic Surgery Journal, Volume 40, Issue 4, April 2020, Pages 460–465.
In the U.S., RECELL is approved for acute thermal burns in patients > 18 years. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Corporate

avita medical

Financial Overview

12 Months Ended June 30

(USD in $000s)	2018	2019	2020	Ytd as of Mar 31, 2021
Revenue	929	5,474	14,263	18,928
Gross Profit	383	4,203	11,290	15,032
BARDA Income	7,734	5,921	3,926	1,615
Cash	10,986	20,174	73,639	114,879

USD $20.14
Share Price[1]

USD $500 Million
Market Capitalization[1]

USD $0.0
(Zero) Debt

Analysts

- Matt O'Brien, Piper (U.S.)
- Josh Jennings, Cowen (U.S.)
- Brooks O'Neil, Lake Street (U.S.)
- Ryan Zimmerman, BTIG (U.S.)
- John Hester, Bell Potter (AUS)
- Chris Kallos, MST (AUS)
- Lyanne Harrison, BofA Global Research (AUS)
- Nicolette Quinn, MorningStar (AUS)
- Shane Storey, Wilsons (AUS)

Nasdaq ticker symbol: RCEL

ASX ticker symbol: AVH

1. RCEL as 5/13/2021

Value-Creating Milestones

Key Accomplishments

- RECELL U.S. revenue growth of 126% *(vs same quarter prior year)*
- Cumulative U.S. product sales since September 2018 FDA approval exceeding $35M
- U.S. Redomiciliation
- Delivery of RECELL units into BARDA Vendor Managed Inventory
- Strong RECELL conference presence (32 presentations to date in ‘21)
- ~50% of Burn Surgeons Used RECELL in CY Q1 ’21
- 73% of Burn Accounts VAC Approved

Upcoming Key Milestones in 2021

- Japan: PMDA Approval – planned CY Q4
- Vitiligo: Last patient enrolled in clinical study – planned CY Q4
- EB: Initial proof of concept for delivery of genetically modified cells in suspension
- Telomerase: Initial proof of concept on impact of telomerase on skin in a mouse model
- Pediatric label expansion
- Outpatient C-Code / TPT

Risk Factors and Disclosures

- There are numerous risk factors involved with the Company's business. Some of these risks can be mitigated by the use of safeguards and appropriate systems and controls, but some are outside the control of the Company and cannot be mitigated. Accordingly, an investment in the Company carries no guarantee with respect to the payment of dividends, return of capital or price at which securities will trade. The following is a summary of the more material matters to be considered. However, this summary is not exhaustive. Potential investor should consult their professional advisors before deciding whether to invest.
- Technological Change: Technological change presents the Company with significant opportunities for growth. However, the risk remains that any competitor may introduce new technology enabling it to gain a significant competitive advantage over the Company.
- Reliance on key personnel: The Company's success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including sub-contractors. The loss of the services of any such personnel could have an adverse effect on the Company.
- Competition: The Company competes with other companies, including nationally in Australia and internationally. Some of these companies have greater financial and other resources than the Company and, as a result, may be in a better position to compete for future business opportunities. There can be no assurance that the Company can compete effectively with these companies.
- Patent Protection: The patent protection that the Company may obtain varies from product to product and country to country and may not be sufficient, including to maintain product exclusivity. Patent rights are also limited in time and do not always provide effective protection for products and services: competitors may successfully avoid patents through design innovation, the Company may not hold sufficient evidence of infringement to bring suit, or the infringement claim may not result in a decision that the rights are valid, enforceable or infringed. Legislation or regulatory actions subsequent to the filing date of a patent application may affect what an applicant is entitled to claim in a pending application and may also affect whether a granted patent can be enforced in certain circumstances. Laws relating to biotechnology remain the subject of ongoing political controversy in some countries. The risk of changed laws affecting patent rights is generally considered greater for the biotechnology field than in other longer established fields.
- Change in government policy and legislation: Any material adverse changes in relevant government policies or legislation of Australia / United States may affect the viability and profitability of the Company, and consequent returns to investors. The activities of the Company are subject to various federal, state and local laws governing prospecting, development, production, taxes, labor standards and occupational health and safety, and other matters.

Important Safety Information

- INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL® device is used by an appropriately-licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds.
- CONTRAINDICATIONS: RECELL® is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann's) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.
- WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.
- PRECAUTIONS: RECELL® is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL® with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% TBSA.
- SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age. For complete Important Safety Information, refer to Instructions For Use.

Revolutionary treatment using a **patient's own skin** for life-changing outcomes

avita medical

Zed, treated with the RECELL® System

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved.

Appendix

avita medical

Skin Injury Framework

RECELL® Autologous Cell Harvesting Device **TARGET INJURY**

	Superficial Wound	Superficial **Partial** Thickness Wound	**Deep Partial** Thickness Wound	**Full Thickness** Wound
Wound Depth				
	1st degree	2nd degree	2nd degree	3rd degree
Wound Size					
	0-9.9%*	10-19.9%	20-29.9%	30-39.9%	40%+

Total Body Surface Area (TBSA) Affected

Adoption Trajectory — Small / Partial Thickness ← Results / Experience ← Large / Full Thickness

For more information on RECELL's indication for use, please go to www.recellsystem.com.

RECELL Process For Autologous Cell Harvesting and Application

1



HARVEST

2

INCUBATE

3

DISAGGREGATE

4

RINSE

5

FILTER

6



APPLY

Thermal Burns: U.S. Target Market Expanded to Include Small Burns and Outpatient

Patient Funnel and Addressable Market



Total Annual Burns in the U.S.

>$600 Million TAM

Severe Burns (as defined as burns > 5% Body Surface Area that may require grafting)

~$260 Million SAM

Target: Severe Burns Treated at Burn Centers (Both In and Outpatient)

Outpatient Pass Thru Code Opens Doors to Small Burns and Expands Serviceable Market Opportunity

U.S. RECELL Commercial Sales Since Approval



Account Adoption Varies By User Type



*Graph is for illustrative purposes only

Super User
~25% Sales

- RECELL used by all surgeons.
- Consistent use across all burns which may require a skin graft"
- Burn Dedicated Team

Standard User
~50% Sales

- Consistent use on a subset of burn types
- Hesitation to expand usage across all burn types and sizes
- Values benefit in large burns

Slow User
~25% of Sales

- Not fully integrated, cautious and use as point of last resort
- Often only 1 surgeon trained, rotating staff, physician turnover
- Often constrained by procurement

Significant Market Opportunity in Repigmenting Stable Vitiligo

OPPORTUNITY ESTIMATION



Prevalence of Vitiligo in the United States

TAM 5.2 Billion

Patients with Stable Vitiligo, eligible for surgical treatment

SAM 750 Million

Estimated number of eligible patients at target call points

Concentrated HCP base: Estimating <1,000 procedural dermatologists and plastic surgeons with interest in treating vitiligo

MARKET TAILWINDS

Growing reimbursement (up to $38,000 / patient annually)

Payers with coverage for vitiligo treatments
(e.g., phototherapy)

United Healthcare · aetna · BlueCross BlueShield · Cigna

OCTOBER 19, 2020
Coverage Update: Cigna to Cover Excimer Laser Treatment for Vitiligo

Not exhaustive

Increasing treatment-seeking behavior

150k — Number of patients seeking treatment in 2013

300k — Number of patients seeking treatment in 2019

Advancing pipeline of disease stabilizing treatments

JAK inhibitors are in late-stage development. Potential to help build market and expand eligible patients

In the United States, RECELL is not approved for use with patients suffering vitiligo.

Soft Tissue Injury Repair: Significant Strategic Overlap to Burns

Synergistic with current commercial focus

OPPORTUNITY ESTIMATION



Significant Unmet Need

Reduction of donor site morbidity and donor site requirements are top unmet needs

Same Treatment Protocol to Burns

Consistent treatment protocol across acute injuries

Strong Interest In RECELL

89% of respondents in surgeon research perceived the RECELL product profile as compelling

Synergistic with Current Commercial Efforts

80% of accounts currently purchasing RECELL also treat for trauma

Reimbursement in Place

Able to leverage existing CPT & outpatient codes

Same Commercial Sales Team

Manageable expansion to cover an additional 222 accounts

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved.

RECELL in Genetic Skin Defects and Rejuvenation

CURRENT PLATFORM

Treatment using RECELL for harvesting and direct reintroduction of the patient's own healthy skin cells



FUTURE PLATFORM

RECELL as a platform for treatment using the patient's corrected skin cells



Gates Center for Regenerative Medicine
UNIVERSITY OF COLORADO / ANSCHUTZ MEDICAL CAMPUS

Gene editing for debilitating orphan skin disorder

HOUSTON Methodist

Molecular reversal of aging for skin rejuvenation

In the U.S., RECELL is approved for acute thermal burns in patients > 18 years only. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Japan Is an Attractive Opportunity for AVITA Medical

- On March 3, 2019, AVITA announced a collaboration with COSMOTEC Company, Ltd, an M3 Group company to market and distribute the RECELL System for the treatment of burns and other wounds in Japan. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange providing services to key global markets in healthcare and life sciences.
- COSMOTEC is pursuing a broad label in Japan which could cover both acute & chronic wounds as well as Vitiligo. They are in active consultations with the PMDA and we anticipate approval to market the RECELL System in Japan on H2 of CY 2021.
- Japan is the second largest healthcare market in the world. Large patient populations coupled with generally attractive reimbursement coverage makes Japan an attractive market for the RECELL System

KEY PATIENT POPULATIONS IN JAPAN

Burn	Vitiligo	Trauma
~6,000 Patients treated severe burns per year	**~2 million** Patients Suffer from Vitiligo	**~22,000** RECELL Eligible Trauma Procedures

Pengzi Zhan et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis†. Annals of medicine 2017
Guest 2017 Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes (48% remained unhealed after 12 months. Excl those which were amputated - conservative.)
Guest 2017 Venous leg ulcer management in clinical practice in the UK: costs and outcome. (53% healed in 12 months)
Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multi-center, hospital based study. J Dermatol. 2011 April; 38(4):310-20
Estimates based on data from 2016 JSBI National Burns Repository and DRG codes -

Health Economic Model Demonstrates RECELL Cost Savings

2019 ABA presentation using Arizona Burn Center data

Total Annual Budget Impact (800 Burn Patients)





Burn Center Costs reduced by $28M (16.2%) net

Inpatient days reduced by 2,422 days (~15%)

Autografting procedures reduced by 811 (~67%)

Total Savings from ACHD use = $31,739,156

Net Savings (incl. ACHD cost) = $28,151,156

Estimated savings of $28 million (16%) annually for single burn center

Foster, K., et al. Budget impact of autologous cell harvesting device (ACHD) use versus standard of care (SOC) for treatment of severe burns: A case study for the Arizona Burn Center. Presented at ABA, April 2019, Las Vegas, NV.